Cancer Research The Future of Cancer Research: Science and Patient Impact  AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 24, 1986-1993, December 1, 1964]
© 1964 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chaube, S.
Right arrow Articles by Murphy, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chaube, S.
Right arrow Articles by Murphy, M. L.

Teratogenic Effects of 5-Chlorodeoxyuridine on the Rat Fetus: Protection by Physiological Pyrimidines*

Shakuntala Chaube and M. Lois Murphy

( Embryology Section, Division of Experimental Chemotherapy, Sloan-Kettering Institute for Cancer Research, New York, New York)

Pregnant Wistar rats received single intraperitoneal injections of 5-chlorodeoxyuridine (ClUdR) on the 12th day of gestation. They were sacrificed on the 21st day and the fetuses examined for gross malformations. For study of skeletal malformations, specimens were fixed in 95 per cent ethanol, cleared and stained in alizarin red, and examined in 100 per cent glycerine. Single doses of 125, 250, 500, and 1000 mg/kg of ClUdR, which did not cause an excessive number of fetal resorptions, produced malformations such as clubbed appendages, poly- and ectrodactylous fore and rear paws, encephaly, cleft palate, and retarded kinky tail in 27, 78, 91, and 100 per cent of the survivors at each of these doses, respectively.

In experiments in which pregnant rats received 500 mg/kg of ClUdR and varying amounts of TdR simultaneously, doses of TdR below 125 mg/kg did not protect against the teratogenic action of ClUdR; but at 250 mg/kg or more of TdR complete protection occurred. In other experiments equal amounts (500 mg/kg) of the two compounds were given separately at time intervals ranging from 15 to 240 minutes. In the group of animals which received the ClUdR after TdR, complete protection occurred up to 30 minutes and partial protection thereafter. Resulting abnormalities were confined exclusively to the rear feet. When ClUdR was given prior to TdR, only 50 per cent of the surviving embryos were normal at 15 minutes (partial protection) and none at 90 minutes.

It is adduced that decline in protective activity of TdR is presumably proportional to the rate of incorporation of ClUdR into the replicating DNA in place of TdR and its rapid degradation in embryonic tissue.

* This Research was supported in part by grants from the American Cancer Society, Inc. (T-40), the Albert and Mary Lasker Foundation, and grants from the National Institutes of Health (CA 03192-08 CY).

Received 7/ 2/64.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1964 by the American Association for Cancer Research.